Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men

Prostate

Volumn 75, Issue 12, 2015, Pages 1255-1263

  Kjær, Thomas Nordstrøm ^a,b   Ornstrup, Marie Juul ^a,b   Poulsen, Morten Møller ^a,b   Jørgensen, Jens Otto Lunde ^a,b   Hougaard, David Michael ^c   Cohen, Arieh Sierra ^c   Neghabat, Shadman ^a   Richelsen, Bjørn ^a,b   Pedersen, Steen Bønløkke ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Immunology and GeneticsStatens Serum Institut   (Denmark)

Author keywords

17 20 lyase; human clinical trial; prostate specific antigen; resveratrol; steroidogenesis

Indexed keywords

ANDROSTANOLONE; ANDROSTENEDIONE; PLACEBO; PRASTERONE; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; RESVERATROL; TESTOSTERONE; ANDROGEN; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE; TESTOSTERONE DERIVATIVE; TUMOR MARKER;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BLOOD BIOCHEMISTRY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE SIZE; PROSTATE VOLUME; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AGED; BLOOD; COMPLICATION; METABOLISM; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

AGED; ANDROGENS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DIHYDROTESTOSTERONE; DOUBLE-BLIND METHOD; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; STILBENES; TESTOSTERONE; TESTOSTERONE CONGENERS; TUMOR MARKERS, BIOLOGICAL;

EID: 84937516678     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23006     Document Type: Article

References (41)

1. Zordoky BN, Robertson IM, Dyck JR,. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta 2015; 1852: 1155-1177.
2. de LM, Timmers S, Schrauwen P,. Resveratrol and obesity: Can resveratrol relieve metabolic disturbances? Biochim Biophys Acta 2015; 1852: 1137-1144.
3. Szkudelski T, Szkudelska K,. Resveratrol and diabetes: From animal to human studies. Biochim Biophys Acta 2015; 1852: 1145-1154.
4. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, Moller N, Jessen N, Pedersen SB, Jorgensen JO,. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013; 62: 1186-1195.
5. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P,. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622.
6. Orsted DD, Bojesen SE,. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 2013; 10: 49-54.
7. Cimino S, Sortino G, Favilla V, Castelli T, Madonia M, Sansalone S, Russo GI, Morgia G,. Polyphenols: Key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012; 2012: 632959.
8. Thompson IM Jr., Cabang AB, Wargovich MJ,. Future directions in the prevention of prostate cancer. Nat Rev Clin Oncol 2014; 11: 49-60.
9. Jasinski M, Jasinska L, Ogrodowczyk M,. Resveratrol in prostate diseases-A short review. Cent European J Urol 2013; 66: 144-149.
10. Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst MW, Pizzo SV, Freedland SJ,. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate 2013; 73: 754-762.
11. Oskarsson A, Spatafora C, Tringali C, Andersson AO,. Inhibition of CYP17A1 activity by resveratrol, piceatannol, and synthetic resveratrol analogs. Prostate 2014; 74: 839-851.
12. Mitchell SH, Zhu W, Young CY,. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 1999; 59: 5892-5895.
13. Yuan H, Pan Y, Young CY,. Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 2004; 213: 155-163.
14. Harada N, Murata Y, Yamaji R, Miura T, Inui H, Nakano Y,. Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 556-560.
15. Streicher W, Luedeke M, Azoitei A, Zengerling F, Herweg A, Genze F, Schrader MG, Schrader AJ, Cronauer MV,. Stilbene induced inhibition of androgen receptor dimerization: Implications for AR and ARDeltaLBD-signalling in human prostate cancer cells. PLoS ONE 2014; 9: e98566.
16. Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G, Ahmed K,. Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol Cancer Ther 2007; 6: 1006-1012.
17. Hudson TS, Hartle DK, Hursting SD, Nunez NP, Wang TT, Young HA, Arany P, Green JE,. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res 2007; 67: 8396-8405.
18. Berry SJ, Coffey DS, Walsh PC, Ewing LL,. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
19. Roehrborn CG,. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am 2011; 95: 87-100.
20. Arnold JT,. DHEA metabolism in prostate: For better or worse? Mol Cell Endocrinol 2009; 301: 83-88.
21. Weihua Z, Lathe R, Warner M, Gustafsson JA,. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA 2002; 99: 13589-13594.
22. Svechnikov K, Spatafora C, Svechnikova I, Tringali C, Soder O,. Effects of resveratrol analogs on steroidogenesis and mitochondrial function in rat Leydig cells in vitro. J Appl Toxicol 2009; 29: 673-680.
23. Yurdagul A Jr., Kleinedler JJ, McInnis MC, Khandelwal AR, Spence AL, Orr AW, Dugas TR,. Resveratrol promotes endothelial cell wound healing under laminar shear stress through an estrogen receptor-alpha-dependent pathway. Am J Physiol Heart Circ Physiol 2014; 306: H797-H806.
24. Nicholson TM, Ricke WA,. Androgens and estrogens in benign prostatic hyperplasia: Past, present and future. Differentiation 2011; 82: 184-199.
25. Chow HH, Garland LL, Heckman-Stoddard BM, Hsu CH, Butler VD, Cordova CA, Chew WM, Cornelison TL,. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: Effects on systemic sex steroid hormones. J Transl Med 2014; 12: 223.
26. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE,. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16: 1246-1252.
27. Walle T,. Bioavailability of resveratrol. Ann NY Acad Sci 2011; 1215: 9-15.
28. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE,. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70: 9003-9011.
29. Polycarpou E, Meira LB, Carrington S, Tyrrell E, Modjtahedi H, Carew MA,. Resveratrol 3-O-D-glucuronide and resveratrol 4'-O-D-glucuronide inhibit colon cancer cell growth: Evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest. Mol Nutr Food Res 2013; 57: 1708-1717.
30. Miksits M, Wlcek K, Svoboda M, Kunert O, Haslinger E, Thalhammer T, Szekeres T, Jager W,. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med 2009; 75: 1227-1230.
31. Andreadi C, Britton RG, Patel KR, Brown K,. Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells. Autophagy 2014; 10: 524-525.
32. Patel KR, Andreadi C, Britton RG, Horner-Glister E, Karmokar A, Sale S, Brown VA, Brenner DE, Singh R, Steward WP, Gescher AJ, Brown K,. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med. 2013; 5: 205ra133.
33. Ornstrup MJ, Harslof T, Kjaer TN, Langdahl BL, Pedersen SB,. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: A randomized placebo-controlled trial. J Clin Endocrinol Metab 2014; 99: 4720-4729.
34. Alberti KG, Zimmet P, Shaw J,. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
35. Szewczuk LM, Forti L, Stivala LA, Penning TM,. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: A mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004; 279: 22727-22737.
36. Juan ME, Maijo M, Planas JM,. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal 2010; 51: 391-398.
37. Vasaitis TS, Bruno RD, Njar VC,. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 2011; 125: 23-31.
38. Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong EN, Kelley CA, Stoner E, Partin AW,. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1998; 159: 449-453.
39. Guess HA, Gormley GJ, Stoner E, Oesterling JE,. The effect of finasteride on prostate specific antigen: Review of available data. J Urol 1996; 155: 3-9.
40. Collins GN, Lee RJ, McKelvie GB, Rogers AC, Hehir M,. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 1993; 71: 445-450.
41. Ku J, Kim ME, Lee NK, Park YH, JO Ahn,. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 2003; 61: 132-136.